Sandbox GGC7

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 17: Line 17:
A mutation of Glu 111 in the active site will render the enzyme inactive or a mutation at Pro 286 will slow down the enzymatic activity. A low functioning or inactive insulin degrading enzyme will allow the buildup of both insulin and amyloid beta-proteins.
A mutation of Glu 111 in the active site will render the enzyme inactive or a mutation at Pro 286 will slow down the enzymatic activity. A low functioning or inactive insulin degrading enzyme will allow the buildup of both insulin and amyloid beta-proteins.
-
For insulin, if it is allowed to build up, insulin resistance can occur and contribute to the development of type II diabetes <ref>doi.org/10.1016/S0002-9440(10)63229-4</ref>. A mutation at Asp 34 will cause Hyperproinsulinemia <ref>doi:10.1210/endo.135.2.8033810</ref><ref>doi:10.1212/01.wnl.0000140292.04932.87</ref>, a disease where the body secretes insulin before it has been fully processed (proinsulin) and so does not function properly.
+
For insulin, if it is allowed to build up, insulin resistance can occur and contribute to the development of type II diabetes <ref>doi:10.1016/s0002-9440(10)63229-4</ref>. A mutation at Asp 34 will cause Hyperproinsulinemia <ref>doi:10.1210/endo.135.2.8033810</ref><ref>doi:10.1212/01.wnl.0000140292.04932.87</ref>, a disease where the body secretes insulin before it has been fully processed (proinsulin) and so does not function properly.
Several different mutations at birth or a young age can contribute to the onset of neonatal diabetes or type I diabetes. The locations are: Asp 24, Arg 32, Ser 32, Gly 43, Val 47, Cys 48, Cys 89, Cys 90, Tyr 96 and Cys 108.
Several different mutations at birth or a young age can contribute to the onset of neonatal diabetes or type I diabetes. The locations are: Asp 24, Arg 32, Ser 32, Gly 43, Val 47, Cys 48, Cys 89, Cys 90, Tyr 96 and Cys 108.

Revision as of 03:53, 16 November 2020

Insulin Protease (Insulin Degrading Enzyme)

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005 May;26(2):19-39. PMID:16278749
  2. Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
  3. Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
  4. Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
  5. doi: https://dx.doi.org/10.1016/s0002-9440(10)63229-4
  6. Gadot M, Leibowitz G, Shafrir E, Cerasi E, Gross DJ, Kaiser N. Hyperproinsulinemia and insulin deficiency in the diabetic Psammomys obesus. Endocrinology. 1994 Aug;135(2):610-6. doi: 10.1210/endo.135.2.8033810. PMID:8033810 doi:http://dx.doi.org/10.1210/endo.135.2.8033810
  7. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004 Oct 12;63(7):1187-92. doi: 10.1212/01.wnl.0000140292.04932.87. PMID:15477536 doi:http://dx.doi.org/10.1212/01.wnl.0000140292.04932.87
  8. Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
  9. doi.org/10.1038/nrd3505
Personal tools